01 Shift from Lab Research to AI-Driven Drug DiscoveryDrug discovery in the biopharma sector is moving from conventional trial and error laboratory experimentation to AI-powered platforms that accelerate the identification and development of new therapeutics. Traditionally, researchers relied on iterative lab experiments, which were time-consuming, costly, and often inefficient in predicting drug performance. Today, AI-driven platforms offer predictive modeling, virtual screening, and simulation tools that enable faster identification of promising drug candidates. Platforms such as Iambic Therapeutics’ “Enchant” demonstrated how AI models forecast early-stage drug performance with higher accuracy than traditional approaches.This AI-enabled approach reduced development costs, shortened timelines, and supports rapid innovation, marking a significant shift toward more efficient and technology-centric drug discovery in the bioconvergence technology market.
02 Growing Use of 3D Bioprinting in Regenerative MedicineThe adoption of 3D bioprinting technologies is emerging as a key trend in the bioconvergence technology market. In the past, tissue engineering and regenerative medicine faced limitations due to reliance on conventional lab-based cell cultures and scaffolding methods. Currently, 3D bioprinting enables the fabrication of complex, functional tissues with high reproducibility, supporting both drug testing and potential transplantation applications. For instance, in March 2024, researchers at the University of Virginia successfully 3D bioprinted functional liver tissue, demonstrating the feasibility of creating tissue models for pharmaceutical testing and regenerative therapies.Hence, growing adoption of 3D bioprinting accelerated innovation in regenerative medicine, facilitated personalized therapies, and strengthened the development of bioconvergence technologies.
01 Growing Approvals and Expanded Use of Cell & Gene TherapiesRecent regulatory approvals and label expansions of advanced biologic therapies are driving the bioconvergence technology market, as more treatments combining biology, engineering, and genetics become available. For instance, in April 2025, the U.S. FDA approved Zevaskyn (pz-cel) developed by Abeona Therapeutics, the first cell-based gene therapy for recessive dystrophic epidermolysis bullosa (RDEB), a rare genetic skin disorder. Thus, increased approvals and broader indications for cell & gene therapies are a major factor fueling demand for bioconvergence platforms.
02 Rising Adoption of Precision Medicine Fuels the Demand for Bioconvergence TechnologiesThe growing focus on personalized and precision medicine is driving demand for bioconvergence technologies, as it combines biology, engineering, and AI to create targeted therapies. The U.S. National Cancer Institute reported that over 45% of new oncology treatments in clinical trials involved precision medicine approaches, including gene and cell-based therapies.Thus, the growing emphasis on personalized treatments is driving the adoption of bioconvergence platforms and supporting market growth.
01 Shortage of Skilled Workforce and Technical ExpertiseThe adoption of bioconvergence technologies is limited by the scarcity of trained professionals in the intersection of biology and computational sciences technologies. The U.S. biotech firms reported that nearly 40% of advanced therapy projects faced delays due to a lack of skilled personnel capable of handling bioinformatics and lab-on-a-chip technologies.Thus, the shortage of qualified personnel remains a significant barrier to the growth of the bioconvergence technology market.
01 Application of Organ-on-Chip Models in Drug TestingGrowing pressure to cut animal use in drug discovery and improve the prediction of human responses is pushing drug developers toward organ-on-chip models, a part of bioconvergence technology. High throughput platforms now let labs culture, maintain, and image many chips at once in a single, closed workstation, streamlining experiments and data capture. Emulate Inc.’s AVA Emulation System, a self-contained organ-on-a-chip workstation that cultures, incubates, and images up to 96 independent chips in parallel, shows how vendor innovation is lowering adoption barriers for pharmaceutical companies and CROs. As these platforms enable faster, more reproducible studies and richer mechanistic readouts, they create clear openings for bioconvergence players across instruments, reagents, software analytics, and contract testing services.
October 2025 Takeda partnered with Nabla Bio to apply generative AI for protein and antibody drug design, advancing bioconvergence between computational modeling and biologic therapeutics development
June 2025 NVIDIA has partnered with Novo Nordisk and the Danish Centre for AI Innovation (DCAI) to advance drug discovery through the integration of AI technologies. This collaboration was focused on utilizing NVIDIA's AI platforms, including BioNeMo, NeMo, NIM, and Omniverse, for accelerating the development of pharmaceutical R&D.
January 2024 AION Labs launched TenAces Biosciences to apply AI and biology for molecular glue drug discovery, advancing the bioconvergence of computational and therapeutic sciences.